Skip to content

Shoichiro Maeda

2 papers in the library · 8 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

Tabernanthalog, a Non-Hallucinogenic Psychedelic, Alleviates Cancer-Induced Cognitive Deficits via Serotonergic Pathways

International Journal of Molecular Sciences August 4, 2025 Masahide Arinaga, Jun Yamada, Shoichiro Maeda et al. 2 citations

Cancer-related cognitive impairment (CRCI)-encompassing anxiety, depression, and memory deficits-significantly diminishes the quality of life in patients with cancer, yet remains underrecognized in clinical practice. In this study, we investigated the therapeutic potential of tabernanthalog (TBG), a non-hallucinogenic analog of psychedelic compounds, as a novel intervention for CRCI using a...

Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia.

Journal of Neurochemistry September 1, 2024 Risako Fujikawa, Jun Yamada, Shoichiro Maeda et al. 6 citations

Recent studies have highlighted the potential involvement of reactive oxygen species (ROS) and microglia, a major source of ROS, in the pathophysiology of schizophrenia. In our study, we explored how the second-generation antipsychotic risperidone (RIS) affects ROS regulation and microglial activation in the hippocampus using a mouse ketamine (KET) model of schizophrenia. KET administration...